NorthStrive Biosciences Launches Phase III AI Drug Discovery Program

NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., has launched Phase III of its AI-driven drug discovery program. This marks a significant advancement in their efforts to leverage artificial intelligence in drug development. The original content was published by PMGC Holdings Inc. on December 17, 2025, and is for informational purposes only.

PMGC Holdings Inc. held annual shareholder meeting

PMGC Holdings Inc. held its Annual Meeting of Shareholders on December 4, 2025. Shareholders elected new board members and ratified the appointment of HTL International, LLC as the independent accounting firm. The potential adjournment of the meeting to solicit additional proxies was approved but not enacted.

PMGC | 10-Q: FY2025 Q3 Revenue: USD 285.95 K

PMGC Holdings’ Subsidiary Achieves ITAR Registration

PMGC Holdings Inc. announced that its subsidiary, AGA Precision Systems LLC, has achieved ITAR registration, enhancing its eligibility as a supplier to defense contractors. This aligns with PMGC's strategy to expand into defense manufacturing. However, Spark's analysis rates ELAB stock as Underperform due to financial weaknesses, including negative revenue and cash flow, and a lack of positive catalysts. PMGC Holdings is a diversified company focused on strategic acquisitions and investments across various industries.

PMGC Holdings Completes Strategic Acquisition of Indarg Engineering

PMGC Holdings Inc. announced the acquisition of Indarg Engineering, a CNC machining company, through its subsidiary AGA Precision Systems LLC. This strategic move aims to enhance PMGC's U.S. manufacturing strategy in aerospace and industrial supply chains. The acquisition is expected to improve earnings scalability and operational synergies. However, ELAB stock is rated as Underperform by Spark due to financial weaknesses and lack of positive catalysts. PMGC Holdings is a diversified company focused on strategic acquisitions across various industries.